Compositions and methods that inhibit il-23 signaling
US-2024425579-A1 · Dec 26, 2024 · US
Method of inhibiting or treating cancer metastasis
US9815906B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9815906-B2 |
| Application number | US-201514621489-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 13, 2015 |
| Priority date | Sep 13, 2010 |
| Publication date | Nov 14, 2017 |
| Grant date | Nov 14, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90α having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of inhibiting or treating cancer metastasis in a subject in need thereof, which comprises administering an inhibitor of a polypeptide consisting of SEQ ID NO:1 to said subject, wherein said inhibitor is a specific antibody against said polypeptide consisting of SEQ ID NO:1, wherein said antibody is MAb E9 produced by the cell line deposited under CGMCC No. 2903 or MAb D10 produced by the cell line deposited under CGMCC No. 2904. 2. The method of claim 1 , wherein said cancer is selected from the group consisting of lung cancer, liver cancer, pancreatic cancer, breast cancer, and cervical carcinoma. 3. The method of claim 1 , wherein said subject has a plasma level consisting of SEQ ID NO:1 of above 200 ng/mL. 4. A method of inhibiting or treating cancer metastasis in a subject with a plasma level of SEQ ID NO:1 that is above 200 ng/mL, comprising: i) detecting a level of the polypeptide consisting of SEQ ID NO:1 in a plasma sample of said subject using an antibody to determine if the patient has a plasma level of SEQ ID NO:1 above 200 ng/mL; and ii) administering a specific antibody against said polypeptide consisting of SEQ ID NO:1 to said subject having a plasma level of SEQ ID NO:1 of above 200 ng/mL, wherein said specific antibody is MAb E9 produced by a cell line deposited under CGMCC No. 2903 or MAb D10 produced by a cell line deposited under CGMCC No. 2904. 5. The method of claim 4 , wherein said cancer metastasis is from a cancer selected from the group consisting of lung cancer, liver cancer, pancreatic cancer, breast cancer, and cervical carcinoma.
Assignees
Inventors
Classifications
phosphorylation · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
comprising antibodies · CPC title
related to diseases not provided for elsewhere · CPC title
specific for leukemia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9815906B2 cover?
- The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90α having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.
- Who is the assignee on this patent?
- Univ Tsinghua, Protgen Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K16/30. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).